September 20, 2001

Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes

.   .   

Landmark randomized controlled trial which showed that, compared with amlodipine, irbesartan reduced the primary composite end point of a doubling of the base-line serum creatinine concentration, the development of end-stage renal disease, or death from any cause in patients with diabetic nephropathy.

Related Articles:

Chronic Kidney Disease, Diabetes, RAS Blockade